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African women in malaria endemic areas get 
pregnant and are at risk of infection with 
3,6Plasmodium falciparum . Among pregnant 
women, studies have shown that the highest 
ndprevalence of malaria infection occurs in the 2  
trimester, with infection rate at delivery and in 
the postnatal period approximating to levels in 
7non-pregnant women . 
Several pregnancy complications like 
miscarriage, preterm labor, intrauterine growth 
restriction (IUGR) and intrauterine fetal death 
(IUFD) have been associated with malaria 
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ABSTRACT
Malaria infection during pregnancy remains an important public health concern especially in the tropics 
with substantial risk for the mother, her fetus and the neonate. More than 25 million African women in 
malaria endemic areas get pregnant and are at risk of infection with Plasmodium falciparum. Several 
pregnancy complications including miscarriage, preterm labor, intrauterine growth restriction (IUGR) and 
intrauterine fetal death (IUFD) have been associated with malaria. In early pregnancy treatment options are 
very limited partly due to drug resistance and the uncertainty about the safety of some antimalarials in 
pregnancy. Quinine still remains safe in all trimesters. A package of interventions for the prevention and 
control of malaria in the African Subregion during pregnancy has been recommended by the World Health 
Organization (WHO). These include intermittent preventive treatment (IPT), use of insecticide treated nets 
(ITNs) and access to effective case management for malaria illness and anemia.
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INTRODUCTION
Malaria infection during pregnancy remains an 
important public health concern especially in 
the tropics with substantial risk for the mother, 
1
her fetus and the neonate . It's estimated in 2010 
that 216 million episodes of malaria occurred 
2
worldwide with resultant 655,000 deaths . Up to 
91% of malaria burden in that year occurred in 
Africa.
Malaria costs Africa an estimated 12 billion US 
3
Dollars in lost production annually . At least 
3,000 people die from malaria every day. 
Malaria also accounts for 40% of public health 
expenditure, 50% of outpatient visits and 30-
50% of hospital admissions in areas where 
4,5
transmission is high . 
Pregnant women and their infants are highly 
vulnerable to malaria. More than 25 million 
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infection. These complications are produced by 
maternal and fetal hyperpyrexia, severe 
maternal and fetal anemia as well as placental 
8 .paras i t i za t ion Areas  wi th  seasona l  
transmission are endemic for malaria infection; 
usually confer a protective semi-immunity 
against Plasmodium falciparum to adult 
16women during the first 10-15 years of life . 
Adult women living in areas of unstable non 
endemic transmission, have no significant 
level of immunity, are more likely to be 
symptomatic when infected and at greater risk 
of having severe disease and of death.
Pathophysiology
Malaria infection develops via two phases: one 
that involves the liver (exoerthrocytic phase) 
and one that involves the red cell (erythrocytic 
phase). When an infected mosquito pierces 
skin to take a blood meal, sporozoites in the 
mosquitos'saliva enter the blood stream and 
migrate to the liver where they infect 
hepatocytes, multiplying asexually and 
asymptomatically for a period of 8-30days.
After potential dormant period in the liver, 
these organisms differentiate to yield 
thousands merozoites, which following rupture 
of their host cells escape into the blood  and 
infect red cells to begin the erythrocytic stage 
of the life cycle. The parasite escapes from the 
liver undetected by wrapping itself in the cell 
membrane of the host liver cell. 
Within the red cell the parasites multiply 
further again asexually, periodically breaking 
out of their host cells to invade fresh red blood 
cells, thus the classical descriptions of waves of 
fever arise from these simultaneous waves of 
merozoites escaping and infecting red blood 
cells. Other merozoites develop in to immature 
gametes or gametocytes. When a fertilized 
mosquito bites and infected person, gametocytes 
are taken up with the blood and mature in the 
mosquito gut, fusing   to form zygote which 
develops in to new sporozoites.
What is the risk of vertical transmission of 
malaria infection to the baby?
Vertical transmission to the fetus can occur 
particularly when there is infection at the time of 
birth and the placenta and cord are blood film 
positive for malaria (Appendix 2).
All neonates whose mothers developed malaria 
in pregnancy should be screened for malaria with 
standard microscopy of thick and thin blood 
films at birth and weekly blood films for 28 day
Malaria transmission Life cycle
Effect of Pregnancy on Malaria
Pregnant women are more susceptible to malaria 
infection when compared to non-pregnant 
women. They are more likely to become infected 
with Plasmodium falciparum malaria with more 
tendency towards increased severity of the 
9,10,11disease . This is partly due to transient 
depression of cell mediated immunity that 
12occurs during pregnancy .
Because of enhanced pancreatic B cell function 
in pregnancy, pregnant women are also prone to 
hyperglycemia and are at risk of symptomatic 
hypoglycaemia when infected with plasmodium 
falciparum, as  a  resul t  of  maternal  
6
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h y p e r i n s u l i n e m i a ,  p a r a s i t e  g l u c o s e  
requirements, maternal glucose requirement 
during febrile illness and decreased oral intake 
13
related to anorexia and emesis .Chondroitin 
sulphate A (CSA) is a ligand that is found on the 
placental syncytiotrophoblast. This ligand is not 
readily accessible on cells elsewhere in the body. 
Parasitized red blood cells (RBCs) found in the 
placentae of primigravidae manifest a 
remarkable preference to binding chondroitin 
sulphate A (CSA). This could explain the 
susceptibility of primigravidae to clinical 
24,25
malaria . Studies have shown that anti 
adhesion immunoglobulin G antibodies against 
chondroitin sulphate A binding parasites are 
associated with protection of maternal malaria 
16
that is developed in subsequent pregnancies .
Effect of Maternal Malarial Infection On 
Pregnancy
The effect of malaria in pregnant woman varies 
with several factors such as the woman 
gravidity, level of immunity, trimester of 
pregnancy and the presence or absence of 
1 4
comorbidity . Low parity, especially 
primigravidae and younger age are more 
15
susceptible to malaria infection “Pregnancy-
associated malaria is characterized by placental 
malaria and the sequestration of malarial 
20
parasites” . Accumulation of plasmodium 
infected erythrocytes in the intervillous space, in 
the placenta, causing histologic changes 
including leukocyte-induced damage to the 
trophoblastic basement membrane is referred to 
21
as placental malaria . This infection can occur in 
22
the absence of clinical symptoms . Placental 
malaria and maternal anemia can precipitate 
23
preterm delivery leading to IUGR . Malaria in 
pregnant women is an important cause of 
stillbirths, and low birth weight, acute 
respiratorydistress syndrome ARDS may 
develop in adults and in up to 25% of pregnant 
women.
Management
Table 1: Schedule of Treatment of Acute 
Malaria
Drug Dosage Route Trimester Complication
Chloroquine All trimester
Quinine 20 mg/kg loading 
dose in 5% dextrose 
over four hours and 

















2.4 mg/kg at 0, 12, 24 





























Primaquine 15 mg and 30 mg 
respectively, daily for 
14 days54
Oral Avoid in a ll 
trimesters
Admit pregnant women with uncomplicated 
malaria to hospital and pregnant women with 
severe andcomplicated malaria to an intensive 
care unit.Intravenous artesunate are the 
treatment of choice for severe falciparum 
malaria. Use intravenousquinine if artesunate is 
not available.Use quinine and clindamycin to 
treat uncomplicated P. falciparum(or mixed, 
such as P.falciparumandP. vivax).Use 
chloroquine to treat P. vivax, P. ovale or P. 
malariae. Primaquine should not be used in 
pregnancy
Acute Malarial Infection
Malaria during pregnancy has adverse effects to 
both mother and the fetus. In early pregnancy 
7
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treatment options are very limited partly due to 
drug resistance and the un certainty about the 
51
safety of some antimalarials in pregnancy . 
Nevertheless, pregnant women with malaria 
must be treated promptly with effective 
antimalarials to clear the parasites. When 
treating pregnant women with malaria 
infection, clinicians have to make treatment 
decisions based on the epidemiological 
resistance pattern, the severity of the infection 
and the available data regarding the safety of the 
anti-malarials. A Cochrane review highlighted 
the lack of qualitative data particularly with 
regard to drug safety in pregnancy; several 
innovations have since shown the improved risk 
52
benefit ratio . 
It's preferable to confirm the diagnosis of 
malaria by laboratory investigations, however, 
where there is strong clinical suspicion, severe 
disease or when it's impossible to obtain prompt 
laboratory diagnosis, presumptive treatment 
can be commenced with available and safe anti 
53
malarials . 
Chloroquine and quinine are safe in all 
trimesters of pregnancy but resistance is not 
uncommon especially with chloroquine.
According to the United Kingdom (U.K.) 
treatment guidelines for severe or complicated 
malaria, regardless of the species of 
Plasmodium parasi tes ,  ar tesunate is  
administered intravenously at a dose of 2.4 
mg/kg body weight at 0, 12 and 24 hours, then 
daily thereafter. Oral artesunate at a dose of 2 
mg/kg once daily is substituted for the 
intravenous one when the patient is well enough 
to take orally with addition of clindamycin. 
When there is no oral artesunate, a three day 
c o u r s e  o f  R i a m e t  ®  ( a r t e m e t h e r  
(20mg)/lumefantrine (120mg) or atovaquone-
proguanil (malarone ®) or a seven day course of 
quinine and clindamycin at 450mg, three times a 
54
day for seven days is administered . 
Many antimalarials are considered not safe in 
pregnancy. Quinine, chloroquine, proquanil, 
pyrimethamine and sulfadoxine-pyrimethamine 
are considered safe in first trimester of 
55
pregnancy . Among them, quinine remains the 
most effective and can be used in all trimesters of 
56
pregnancy . WHO has also recommended the 
use of artemisinin combination therapy (ACT) in 
the first trimester if it's the only treatment 
55,57
available . The other alternative treatment for 
severe or complicated malaria is the use of 
intravenous quinine 20 mg/kg loading dose (no 
loading dose for those who have taken quinine or 
mefloquine) in 5% dextrose over four hours and 
then 10 mg/kg intravenously over four hours. In 
addition, clindamycin at a dose of 450 mg is 
added intravenously every four hours. Quinine 
dose should not exceed 1.4 g. oral quinine is 
substituted for intravenous when the patient can 
tolerate at a dose of 600 mg three times a day for 
54
seven days . Where treatment with intravenous 
quinine extends beyond 48 hours or the patient 
has renal or hepatic dysfunction, quinine dosing 
58
should be reduced to 12 hourly . For 
uncomplicated malaria infection due to 
Plasmodium falciparum, oral quinine is 
administered at a dose of 600 mg eight hourly 
and oral clindamycin 450 mg eight hourly for 
seven days. Those that cannot tolerate oral 
quinine, Riamet or atovaquone –proquanil 
combination can be used for uncomplicated 
54
malaria . In a situation where pregnant women 
present with complicated malaria, quinine 10 mg 
/kg can be administered intravenously in 5% 
dextrose over four hours every eight hours plus 
intravenous clindamycin 450 mg every eight 
hours. When the patient can tolerate oral 
medications with no vomiting, oral quinine can 
8
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be switched at a dose of 600 mg three times a day 
to complete five to seven days. Oral clindamycin 
can also be switched at 450 mg three times a day 
54for seven days if the need arise . Non falciparum 
malaria (P. ovale, P. vivax and P. malariae) are 
treated with oral chloroquine (base) drug at a 
dose of 600 mg followed by 300 mg 68 hours 
later. Then, 300 mg on day two and day three 
54based on the U.K. treatment guidelines . 
Resistant P. vivax is treated like uncomplicated 
54P. falciparum . P. ovale and P. vivax are treated 
with oral primaquine at a dose of 15 mg and 30 
54mg respectively, daily for 14 days .
Oral chloroquine at a dose of 300 mg can be 
administered weekly to prevent relapse until 
delivery; following delivery, treatment should 
be postponed until three months after, following 
54G6PD testing . Although exchange blood 
transfusion has not been proven beneficial in a 
randomized controlled trial, it has been an option 
59in the treatment of severe malaria since 1974 . 
For severe malaria with parasite density of more 
than 10%, Centre for Disease Control and 
Prevention (CDC) recommends exchange blood 
transfusion. This is assumed to have beneficial 
effects by removing infected red cells, 
improving the rheological properties of blood 
and reducing toxic factors such as parasite-
derived toxins, harmful metabolites and 
59cytokines . The fever developed following 
malaria infections has been associated with 
60,61 62premature labour and fetal distress . 
Treatment with antipyretics like paracetamol at 
54standard dose is found to be effective . Other 
associated complications like mild to moderate 
anemia in pregnancy following malaria 
infection can be treated with ferrous sulphate 
54and folic acid
Prophylaxis
Despite aneed, no effective vaccine currently 
exists, although efforts to develop one are 
ongoing. Several medications are available to 
prevent malaria in pregnancy and to prevent 
malaria in travellers to malaria –endemic 
countries.
The 'ABCD' of malaria prevention is a useful 
formula to remember the components are
·Awareness of risk 
·Bite prevention 
·Chemoprophylaxis 
·Diagnosis and treatment which must be 
prompt
Intermittent Preventive Therapy
The use of IPT with sulfadoxine and 
pyrimethamine (SP) for the control of malaria in 
pregnancy in areas of moderate to high 
transmission was adopted by the WHO Expert 
26Committee on Malaria in 1998 . Hitherto, the 
prevention of malaria in pregnancy relied on 
weekly chloroquine prophylaxis, though 
27,28chloroquine was effective . Poor compliance 
was the problem even before the emergence and 
29widespread of drug resistance .
The purpose of IPT is to reduce the risk of low 
birth weight (LBW) and maternal anemia by 
clearing asymptomatic placental and peripheral 
parasitemia and providing pregnant women with 
protection against malaria infection between 
30antenatal consultations . It was recommended 
by the WHO, the administration of two to three 
courses of SP (three tablets each contained 500 
mg of sulfadoxine and 25 mg of pyrimethamine) 
after fetal quickening with each course 
administered not less than one month apart and 
31all before the last four weeks of pregnancy . 
This IPTp is adopted as a national policy in 37 
countries, 33 of which are in Sub-Saharan 
32Africa .
10
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Data from recent observational studies in 
Malawi, the first country where IPT-SP was 
implemented in 1993, revealed reduced 
33
effectiveness of SP for IPT . There is also a 
growing concern about the decreasing 
effectiveness of the two dose regimen of SP for 
IPT in other countries with high level of 
resistance to SP especially in Southern and 
Eastern African region where the prevalence of 
34
HIV is highest in the world . It's similarly 
observed that the HIV positive women require 
more doses of SP for IPTp to have effective 
protection against malaria in pregnancy than 
35
women who are HIV negative .
According to the recent recommendation by the 
Evidence Review Group (ERG) of the Global 
1
Malaria Programme , they suggest that, inspite 
of the increased prevalence in Plasmodium 
falciparum of molecular markers associated 
with resistance to SP (based on quintuple 
mutant dhps/dhfr haplotypes prevalence), in 
Sub-Saharan Africa, IPT-SP remains effective 
at preventing peripheral parasitaemia, maternal 
anemia and clinical malaria during pregnancy 
and is associated with reduced neonatal 
36-40
mortality .
The evidence review group (ERG) of the Global 
Malaria Programme also commented on the 
number of IPTp doses that need to be 
administered during pregnancy to achieve the 
1
maximal beneficial effect of IPTp . An 
unpublished meta-analysis by Kayentao and 
colleagues which comprised seven controlled 
trials conducted in five Sub-Saharan African 
countries from 1994 to 2008, revealed three 
more doses of IPTp with SP was superior to the 
standard two dose regimen, regardless of the 
HIV status and gravidity of the pregnant woman 
1
in preventing low birth weight . The study also 
showed that women who received a median of 
four doses of IPTp when compared with those on 
the two doses regimen also had a lower risk of 
moderate to severe maternal anemia, maternal 
1
malaria at delivery and placental malaria .
Other recommendations by the Evidence 
Review group include the administration of the 
last dose of IPTp with SP even after 36 weeks of 
gestation without safety concerns and the 
administration of IPTp as directly observed 
1
therapy . Administration of SP to patient on 
cotrimoxazole prophylaxis is contraindicated. 
Also the concomitant administration of SP with 
at least 5 mg of folic acid to pregnant women is 
contraindicated because folic acid reduces the 
efficacy of the antimalarial. However, SP can be 
1
administered even in an empty stomach .
Several studies have mentioned the potential 
41-43
alternatives to SP for IPTp  with mefloquine 
and azithromycin based combination being the 
leading candidates under study. A randomized 
clinical trial in Benin (n=1601) demonstrated 
mefloquine to be more superior to SP in 
preventing placental malaria (prevalence 1.7 vs 
4.4% of women; p=0.005) and clinical malaria 
(incidence: 26 cases per 10,000 person-months 




It was in 1897 that the transmission of malaria by 
the bites of Anopheles mosquitoes was 
discovered by Ronald Ross. Immediately after 
his discovery, he realized that due to the fact 
these mosquitoes bite at night, bed nets should be 
45
a useful protection against malaria infection . It 
was in the 1980s when insecticides began to be 
applied to bed nets, which greatly found to 
increase their effectiveness in reducing malaria 
45
infection even when the bed nets are torn . Fast 
acting synthetic insecticides, which are certified 
11
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safe by WHO like deltamethrin (k-othrine) at 
2
0.025 grams/m  of netting, alphacypermethrin 
2
(fendona) at 0.02 grams/m , lampdacyhalothrin 
2
(icon) at 0.01 grams/m  and etofenprox (vectron) 
2
at 0.20 grams/m have been available and they all 
add a chemical barrier to the net's imperfect 
45
physical barrier .
Studies have shown that the use of insecticide 
treated nets reduces anemia and the prevalence 
and density of malaria parasitemia in pregnancy 
especially in areas of intense and perennial 
46-48
malaria transmission . 
In a systematic review of randomized controlled 
trials on the benefits of insecticides treated nets 
for the prevention of malaria in pregnancy; the 
review showed that women of low gravidity 
randomized to insecticides treated nets (ITNs) 
delivered fewer LBW babies and were less 
likely to experience either miscarriage or 
49
abortion . Despite the reduction in malaria 
infections found in the studies, there was no 
demonstrable overall effect on mean 
hemoglobin and data on maternal anemia were 
49
inconsistent .
Another trial which was conducted in Thailand 
Myanmar border compared ITNs to untreated 
nets. The area is characterized by a highly 
seasonal Plasmodium falciparum and 
Plasmodium vivax malaria infection. The study 
showed a statistically significant reduction in 
anemia and fetal loss in all gravidae but no 
50
benefit on birth weight or gestational age .
Postnatal Care
Chemoprophylaxis for breastfeeding women
Mefloquine (5mg/kg once a week) is the 
recommended drug of choice for prophylaxis in 
the second and thirdtrimesters for chloroquine-
resistant areas. With very few areas in the world 
free from chloroquine resistance, mefloquine is 
essentially the only drug considered safe for 
prophylaxis in pregnant traveller Vertical 
transmission to the fetus can occur particularly 
when there is infection at the time of birth and 
the placenta and cord are blood film positive for 
malaria 
All neonates whose mothers developed malaria 
in pregnancy should be screened for malaria 
withstandard microscopy of thick and thin blood 
films at birth and weekly blood films for 28 
days.
Pregnancy Counseling
Women planning pregnancy and travelling to a 
destination where there is a risk of contracting 
malaria should be advised there may be harmful 
consequences for the pregnancy. Prophylaxis is 
not 100% effective and malaria is associated 
with increased risk of miscarriage. Women 
should be advised not to travel or to choose an 
alternative destination. If it not possible to delay 
either the pregnancy or the travel plan, advice 
from a specialist with current experience of 
malaria should be sought (Box 2). Chloroquine 
and proguanil are not efficacious in 
chloroquine-resistant areas and cannot be 
recommended because of this.85There are very 
few chloroquine-sensitive areas remaining. To 
avoid completely any potential adverse drug 
effects from preconceptual and first-trimester 
exposure, it is advisable to wait for complete 
excretion of the drug, if it was taken for 
prophylaxis, before becoming pregnant (Table 
3). Nevertheless, unplanned conception while 
taking malaria prophylaxis is not considered a 
reason to recommend termination of pregnancy, 
owing to the low risk of teratogenicity
12
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CONCLUSION
Malaria is a mosquito-borne infectious disease 
caused by the genus plasmodium, beginning 
with bite from an infected female anopheles. 
Several pregnancy complications like severe 
anaemia miscarriage,  preterm labor,  
intrauterine growth restriction (IUGR) 
Reduction of birth weight and intrauterine fetal 
death (IUFD) have been associated with 
malaria infection. Disease transmission can be 
reduced byintermittent preventive treatment 
(IPT), access to effective case management for 
malaria illness and preventing mosquito bites- 
by distribution of mosquito nets (ITN) and 
insects' replants or with mosquito control 
measures such as spraying insecticides and 
draining standing water.
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